An increased grafting probability was observed also for higher stage tumours (p = 0.041 for Stage II, III, IV vs. Stage I and p = 0.038 for Stage III,IV vs. Stage I,II) and tumours with higher CD133+/CXCR4+/EpCAM− subpopulation (p = 0.019) whereas a trend towards increased grafting for tumours with SUVmax higher than 8 (p = 0.084) was observed (Table 1). Here, EPCAM is linked to neoplasm.